Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
회사 코드IBO
회사 이름Impact Biomedical Inc
상장일Sep 16, 2024
설립일2018
CEOMr. Frank D. Heuszel, CPA
직원 수2
유형Ordinary Share
회계 연도 종료Sep 16
주소1400 Broadfield Blvd.
도시HOUSTON
증권 거래소NYSE American Consolidated
국가United States of America
우편 번호77084
전화15852321500
웹사이트https://www.impactbiomedinc.com/
회사 코드IBO
상장일Sep 16, 2024
설립일2018
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음